Maravai LifeSciences Offers End-to-End mRNA Production with the Launch of TriLink BioTechnologies' Plasmid DNA Manufacturing ...
15 March 2021 - 11:05PM
Maravai LifeSciences (NASDAQ: MRVI), a global provider of life
science reagents and services to researchers and biotech
innovators, has expanded its contract development and manufacturing
organization (CDMO) capabilities at TriLink BioTechnologies
(“TriLink”) with the launch of its plasmid DNA (pDNA) manufacturing
services. TriLink’s new plasmid services empower customers with the
ease of an end-to-end messenger RNA (mRNA) solution from a single
partner – with Current Good Manufacturing Practice (cGMP)
capabilities from plasmid production through final release testing.
“The ability to work with an expert, end-to-end manufacturing
partner such as TriLink comes at a critical time for the
pharmaceutical industry, when global demand for mRNA is expected to
exceed the availability of GMP-quality plasmid DNA,” said Carl
Hull, CEO of Maravai LifeSciences. “By integrating pDNA production
with our pioneering mRNA services, we believe TriLink will
dramatically reduce production timelines and overcome tech transfer
bottlenecks by reducing or eliminating plasmid sourcing wait-times
that could otherwise last months.”
Plasmid is a critical raw material for a wide variety of
therapeutic needs, such as novel gene editing and cell therapy
applications, including CAR-T therapies, as well as for mRNA
vaccine technologies, like those enabling several in-market and
emerging Covid-19 vaccines.
By also enabling customers with its revolutionary CleanCap® mRNA
capping technology and more than two decades of specialist
experience manufacturing modified nucleotides, TriLink seeks to
further optimize mRNA production and help accelerate customers’
project timelines.
“Leveraging our deep mRNA knowledge and expertise, we seek to
help our customers to manage the complexities, minimize the risks,
and streamline the design process to and through clinical trials,”
added Brian Neel, Chief Operating Officer of TriLink
BioTechnologies.
TriLink’s pDNA capabilities offer manufacturing for GMP-grade
plasmid, and can be customized with our flexible GMPLink™ grade to
meet customer specific clinical needs. Its 118,000 square foot,
state-of-the-art manufacturing facility includes 7 custom designed
GMP suites dedicated to plasmid development and production, which
enables TriLink to support customer programs from milligram through
multigram scales.
In addition, TriLink’s plasmid manufacturing suites utilize
leading automation and control platforms, including automated
ultrafiltration and diafiltration processes. Analytical testing and
mRNA production capabilities are also conveniently available
onsite.
“We’re meeting growing customer needs for a one-stop shop for
plasmid and mRNA development and manufacturing services,” adds COO
Brian Neel. “Customers have been very positive about our end-to-end
offering thus far, and we look forward to doing even more to
support our customers going forward.”
To learn more about Maravai LifeSciences,
visit www.maravai.com. To learn more about
TriLink BioTechnologies and the new plasmid manufacturing services
offering,
visit https://www.trilinkbiotech.com/plasmid-manufacturing.
About Maravai
Maravai is a leading life sciences company providing critical
products to enable the development of drug therapies, diagnostics,
novel vaccines and support research on human diseases. Maravai’s
companies are leaders in providing products and services in the
fields of nucleic acid synthesis, bioprocess impurity detection and
analysis, and protein labeling and detection to many of the world's
leading biopharmaceutical, vaccine, diagnostics, and cell and gene
therapy companies.
For more information about Maravai LifeSciences, visit
www.maravai.com.
About TriLink BioTechnologies
TriLink BioTechnologies, part of Maravai LifeSciences, is a CDMO
helping life science leaders and innovators overcome challenges in
the synthesis and scale-up of nucleic acids, NTPs and mRNA capping
analogs with scale-up expertise and unique mRNA production
capabilities, including its proprietary CleanCap® mRNA capping
technology. TriLink continues to expand its cGMP and general
manufacturing capacity at its new global headquarters to support
mRNA, oligonucleotide & plasmid therapeutic, vaccine and
diagnostic
customers. www.trilinkbiotech.com
Forward-looking Statements
This press release contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Investors are cautioned
that statements in this press release which are not strictly
historical statements constitute forward-looking statements,
including, without limitation, statements regarding the advantages
of an end-to-end mRNA solution from a single supplier, demand for
mRNA, demand for GMP-quality plasmid DNA, and advantages of
CleanCap mRNA technology constitute forward-looking statements and
are identified by words like “believe,” “expect,” “may,” “will,”
“should,” “seek,” “anticipate,” or “could” and similar expressions.
Such forward-looking statements are subject to a number of risks
and uncertainties that could cause actual results to differ
materially from those anticipated, including, without limitation
and uncertainties related to the level of demand for our products
and services, continued validation of the safety and effectiveness
of our technology, new scientific developments and competition from
other products. These and other risks and uncertainties are
described in greater detail in the section entitled “Risk Factors”
in Maravai’s Prospectus dated November 19, 2020 on file with the
U.S. Securities and Exchange Commission. Actual results may differ
materially from those contemplated by these forward-looking
statements, and therefore you should not rely upon them. These
forward-looking statements reflect our current views and we do not
undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date hereof except as required by law.
Contact Information:
Media Contact: Sara Michelmore
MacDougall
+1 781-235-3060
maravai@macbiocom.com
Investor Contact: Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
ir@maravai.com
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Apr 2023 to Apr 2024